BD has completed the first prophylactic Phasix™ Mesh laparotomy case in Greece following expanded EU approval, while advancing a global clinical trial to support incisional hernia prevention.
BD (Becton, Dickinson and Company) has reached a key milestone in its advanced tissue regeneration strategy with the completion of the first prophylactic laparotomy reinforcement procedure using Phasix™ Mesh in Greece. The case follows the recent expansion of the product’s indication in Europe, marking the first broad prophylactic approval for hernia mesh use across open, high-risk surgical procedures in the European Union.
The procedure was performed at George Papanikolaou General Hospital of Thessaloniki, one of northern Greece’s largest hospitals, under the leadership of general surgeon and Associate Professor Ioannidis Orestis. The patient, a 63-year-old man with multiple risk factors, underwent a sigmoidectomy during which an 08 x 30 cm Phasix™ Mesh was placed prophylactically at the laparotomy incision site to help reduce the risk of future incisional hernia formation.
At the same time, BD continues to advance its PREVENT multicenter randomized controlled trial, which is being conducted across clinical sites in Europe and the United States. The study has already enrolled more than 85% of its target population and is expected to complete enrollment in 2026. The trial is designed to generate robust clinical evidence supporting the use of prophylactic bioabsorbable mesh to lower incisional hernia rates and to support a Premarket Approval submission for an incisional hernia prevention indication in the U.S.
Click here to join our WhatsApp channel here
“Incisional hernias affect up to 30% of patients after abdominal surgery and cost health care systems billions annually,” said Rian Seger, worldwide president of the BD Surgery business. “With Phasix™ Mesh, we’re not just repairing hernias, we’re preventing them. This milestone reflects our commitment to improving long-term patient outcomes.”
